DOCSLIB.ORG

Regulation of Jak–Stat Signalling in the Immune System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulation of Jak–Stat Signalling in the Immune System REVIEWS REGULATION OF JAK–STAT SIGNALLING IN THE IMMUNE SYSTEM Ke Shuai*‡ and Bin Liu* The cytokine-activated Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses. Dysregulation of JAK–STAT signalling is associated with various immune disorders. The signalling strength, kinetics and specificity of the JAK–STAT pathway are modulated at many levels by distinct regulatory proteins. Here, we review recent studies on the regulation of the JAK–STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases. Cytokines have essential roles in the control of immune which is located at the carboxyl terminus8,9.The amino- responses. The biological functions of cytokines mainly terminal region of STATs is involved in regulating STAT depend on cytokine-mediated gene activation or repres- activity, such as the formation of STAT tetramers10 and sion. Studies on gene induction by interferons (IFNs) led tyrosine dephosphorylation11. to the discovery of the Janus kinase (JAK)–signal trans- Genetic knockout studies have shown that JAKs ducer and activator of transcription (STAT) pathway1, and STATs have highly specific functions in the con- which has since been shown to be a common signalling trol of various immune responses12–14 (TABLE 1). pathway used by many cytokines. The binding of a Recent studies have shown that JAK–STAT signalling cytokine to its cell-surface receptor results in receptor can be regulated at many steps through distinct dimerization and the subsequent activation of JAK tyro- mechanisms. Key regulators include the suppressor sine kinases, which are constitutively associated with the of cytokine signalling (SOCS) proteins and the receptor. Specific tyrosine residues on the receptor are recently discovered protein inhibitor of activated then phosphorylated by activated JAKs and serve as STAT (PIAS) family, as well as various protein tyro- docking sites for a family of latent cytoplasmic transcrip- sine phosphatases (PTPs). The modulation of JAKs tion factors known as STATs.STATs are phosphorylated and STATs by various protein modifications and the by JAKs, then dimerize and subsequently leave the recep- cross-talk between different JAK–STAT pathways and tor and translocate to the nucleus, where they activate other cellular signalling pathways provide additional gene transcription2,3 (FIG. 1a). levels of regulation that might be crucial. This review The mammalian JAK family has four members: discusses the latest insights into how these various JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2)4.Each mechanisms regulate JAK–STAT signalling in the contains a conserved kinase domain and a related, but immune system. *Division of Hematology- catalytically inactivate, pseudo-kinase domain at the Oncology, Department of carboxyl terminus (FIG. 1b).The pseudo-kinase domain The regulation of JAKs Medicine and ‡Department of Biological Chemistry, might regulate the kinase activity of JAKs. JAKs are mainly regulated at the post-translational University of California, There are seven mammalian STATs: STAT1, STAT2, level through various mechanisms (FIG. 2). Los Angeles, California STAT3, STAT4, STAT5A, STAT5B and STAT6 (REF. 2), 90095, USA. which are highly homologous in several regions (FIG. 1c), Regulation of JAKs by the SOCS proteins. SOCS pro- Correspondence to K. S. including a SRC homology 2 (SH2) domain, which is teins are the most thoroughly studied regulators of e-mail: kshuai@mednet. 5,6 ucla.edu involved in the activation and dimerization of STATs ,a JAK–STAT signalling. Biochemical and genetic studies doi:10.1038/nri1226 DNA-binding domain7, and a transacivation domain , have clearly shown a crucial role for SOCS proteins in 900 | NOVEMBER 2003 | VOLUME 3 www.nature.com/reviews/immunol REVIEWS a involvement of SOCS proteins in the degradation of sig- Cytokine nalling proteins through the ubiquitin-proteasome Cytokine receptor pathway (BOX 1) has also been suggested. The SOCS box can bind to elongins B and C, which are known compo- nents of a ubiquitin E3 ligase complex26,27.So,SOCS JAK JAK proteins might target signalling proteins for degradation. The regulation of SOCS3 by cytokines can also occur at the post-translational level. It has been docu- mented that SOCS3 becomes rapidly phosphorylated at residues Tyr204 and Tyr221, which are present in the STAT Y STAT Y P conserved SOCS box, by JAKs and receptor tyrosine Y P STAT kinases in response to certain cytokine and growth- factor stimulation28,29.Mutational studies indicate that Nucleus tyrosine phosphorylation of SOCS3 accelerates the PY STAT degradation of SOCS3 protein, thereby regulating 30 STAT Y P feedback inhibition of JAK–STAT signalling . Gene-targeting studies indicate that SOCS1 and Transcription SOCS3 have essential roles in the regulation of immune functions (TABLE 1). Socs1–/– mice die within three weeks b Pseudo-kinase Kinase γ 31–34 domain domain of birth, mainly due to dysregulated IFN- responses . JH7 JH6 JH5 JH4 JH3 JH2 JH1 Socs1–/– mice show lymphopaenia, increased apoptosis JAK N YY C in lymphoid organs and increased levels of IFN-γ in the P P serum. Socs3 knockout is embryonic lethal, probably due to placental insufficiency and erythrocytosis35–37. c Amino-terminal Coiled-coil DNA-binding Linker SH2 Transactivation Conditional Socs3 gene-targeting studies have shown an domain domain domain domain domain domain STAT N YSC important role for SOCS3 in the negative regulation of 38–40 ?? P P interleukin-6 (IL-6) signalling in macrophages . Met ISG15 Ace SUMO Earlier studies indicated that both SOCS1 and SOCS3 are induced by IFΝ-γ and IL-6, and both can inhibit Figure 1 | The JAK–STAT pathway. a | A schematic representation of the Janus kinase IFN-γ and IL-6 responses. However, recent genetic stud- (JAK)–signal transducer and activator of transcription (STAT) pathway. The activation of JAKs ies have shown an unexpected in vivo specificity of after cytokine stimulation results in the phosphorylation of STATs, which then dimerize and SOCS1 and SOCS3 in the regulation of cytokine sig- translocate to the nucleus to activate gene transcription. b | The domain structure of JAKs. nalling. In Socs3–/– macrophages, the activation of STAT1 The domains JH1–JH7 are based on sequence similarity of four known JAKs. JH1 is the kinase by IL-6 is prolonged, whereas the activation of STAT1 by domain, which contains two tyrosines that can be phosphorylated after ligand stimulation. JH2 γ 38–40 –/– is the pseudo-kinase domain. The JH6 and JH7 domains mediate the binding of JAKs to IFN- is normal .By contrast, in Socs1 macro- receptors. c | The domain structure of STATs. The activity of STATs can be regulated by protein phages, the opposite is true. In addition, although STAT3 modification, including tyrosine and serine phosphorylation, methylation (Met), sumoylation is activated by both IL-6 and IL-10, the tyrosine phos- (SUMO), ISGylation (ISG15) and acetylation (Ace). The modification sites of ISGylation and phorylation of STAT3 induced by IL-6, but not IL-10, is acetylation have not been identified. prolonged in Socs3–/– macrophages. So, SOCS proteins have specificity for cytokines, but not JAKs or STATs. An interesting property of SOCS proteins is that they the immune system. The SOCS family of proteins has specifically affect the kinetics of JAK–STAT-signalling ter- eight members: CIS (cytokine-inducible SH2 domain mination, but have no effect on the initial activation protein) and SOCS1–SOCS7 (REFS 15,16).SOCS proteins process or signalling strength. As a result, prolonged STAT contain an SH2 domain, which is flanked by a variable activation induced by cytokines is observed in the absence amino-terminal domain and a carboxy-terminal SOCS of SOCS proteins. As discussed later, prolonged STAT box17 (FIG. 3a).Among the SOCS family, the roles of activation might lead to altered cytokine responses. In SOCS1, SOCS2, SOCS3 and CIS have been well studied fact, microarray analysis shows that the gene-activation in the regulation of JAK–STAT signalling18.These SOCS profile induced by IL-6 mimics that induced by IFN-γ in proteins are generally expressed at low levels in unstimu- Socs3–/– cells, indicating a role for SOCS3 in the control lated cells and become rapidly induced by cytokines, of cytokine-response specificity38,39.A similar alteration thereby inhibiting JAK–STAT signalling and forming a of the IL-6 response has also been observed in Stat3–/– classic negative-feedback loop19.SOCS proteins inhibit cells, in which STAT1 activation is prolonged41. cytokine signalling through distinct mechanisms (FIG. 3b). SOCS proteins have also been implicated in cross- The SH2 domain of SOCS1 binds directly to tyrosine talk between different cytokine-signalling pathways, as phosphorylated JAKs, resulting in the direct inhibition of discussed later. JAK activity20–22.However, the inhibition of JAKs by SOCS3 requires binding of SOCS3 to the activated Regulation of JAKs by protein tyrosine phosphotases. receptor23,24.Instead of acting on JAKs, CIS seems to Several PTPs have been indicated to regulate JAKs, inhibit STAT activation by competing with STATs for including SHP1, SHP2, CD45, PTP1B and T-cell PTP binding to the receptor docking sites25. Finally, the (TCPTP). SHP1 and SHP2 are SH2-domain-containing NATURE REVIEWS | IMMUNOLOGY VOLUME 3 | NOVEMBER 2003 | 901 REVIEWS PTPs42. SHP1 is mainly expressed by haematopoietic JAK2 and TYK2, but not JAK1, can serve as substrates of cells and has been shown to be physically associated PTP1B49, and increased JAK2 phosphorylation has with the IL-3 receptor β chain, the c-KIT receptor, and been observed in Ptp1b–/– mouse embryo fibroblasts. the erythropoietin receptor (EPOR). Cells expressing In addition, PTP1B has been implicated in the negative a mutant EPOR that is defective in SHP1 binding regulation of LEPTIN signalling, possibly by targeting are hypersensitive to EPO and have prolonged EPO- JAK2 (REFS 50,51).However, no immunological pheno- induced autophosphorylation of JAK2, indicating a role type of PTP1B has been reported.
Load more

Recommended publications
  • Activation of Smad Transcriptional Activity by Protein Inhibitor of Activated STAT3 (PIAS3)
    Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3) Jianyin Long*†‡, Guannan Wang*†‡, Isao Matsuura*†‡, Dongming He*†‡, and Fang Liu*†‡§ *Center for Advanced Biotechnology and Medicine, †Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, and ‡Cancer Institute of New Jersey, 679 Hoes Lane, Piscataway, NJ 08854 Communicated by Allan H. Conney, Rutgers, The State University of New Jersey, Piscataway, NJ, November 17, 2003 (received for review August 22, 2003) Smad proteins play pivotal roles in mediating the transforming of many transcription factors through distinct mechanisms. growth factor ␤ (TGF-␤) transcriptional responses. We show in this PIAS1 and PIAS3 bind and inhibit STAT1 and STAT3 DNA- report that PIAS3, a member of the protein inhibitor of activated binding activities, respectively (19, 20). PIASx␣ and PIASx␤ STAT (PIAS) family, activates TGF-␤͞Smad transcriptional re- were identified through interactions with the androgen receptor sponses. PIAS3 interacts with Smad proteins, most strongly with and the homeodomain protein Msx2, respectively (21, 22). Smad3. PIAS3 and Smad3 interact with each other at the endog- PIASx␣ and PIASx␤ inhibit IL12-mediated and STAT4- enous protein level in mammalian cells and also in vitro, and the dependent gene activation (23). PIAS1, PIAS3, PIASx␣, and association occurs through the C-terminal domain of Smad3. We PIASx␤ also regulate transcriptional activation by various ste- further show that PIAS3 can interact with the general coactivators roid receptors (21, 24–26). PIASy has been shown to antagonize p300͞CBP, the first evidence that a PIAS protein can associate with the activities of STAT1 (27), androgen receptor (28), p53 (29), p300͞CBP.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • An Immunoevasive Strategy Through Clinically-Relevant Pan-Cancer Genomic and Transcriptomic Alterations of JAK-STAT Signaling Components
    bioRxiv preprint doi: https://doi.org/10.1101/576645; this version posted March 14, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components Wai Hoong Chang1 and Alvina G. Lai1, 1Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, OX3 7FZ, United Kingdom Since its discovery almost three decades ago, the Janus ki- Although cytokines are responsible for inflammation in nase (JAK)-signal transducer and activator of transcription cancer, spontaneous eradication of tumors by endoge- (STAT) pathway has paved the road for understanding inflam- nous immune processes rarely occurs. Moreover, the matory and immunity processes related to a wide range of hu- dynamic interaction between tumor cells and host immu- man pathologies including cancer. Several studies have demon- nity shields tumors from immunological ablation, which strated the importance of JAK-STAT pathway components in overall limits the efficacy of immunotherapy in the clinic. regulating tumor initiation and metastatic progression, yet, the extent of how genetic alterations influence patient outcome is far from being understood. Focusing on 133 genes involved in Cytokines can be pro- or anti-inflammatory and are inter- JAK-STAT signaling, we found that copy number alterations dependent on each other’s function to maintain immune underpin transcriptional dysregulation that differs within and homeostasis(3).
    [Show full text]
  • Role of STAT1 in the Resistance of HBV to IFN‑Α
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 21: 550, 2021 Role of STAT1 in the resistance of HBV to IFN‑α BINGFA XU1, BO TANG2 and JIAJIA WEI3 1Department of Pharmacy, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230061; 2Department of Pharmacy, Huainan First People's Hospital, Huainan, Anhui 232007; 3Department of Pharmacy, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213000, P.R. China Received February 26, 2020; Accepted February 17, 2021 DOI: 10.3892/etm.2021.9982 Abstract. The objective of the present study was to explore of the receptor. This subsequently changes the intracellular the mechanism of hepatitis B virus (HBV) resistance to inter‑ conformation of the receptor and activates janus kinase (JAK). feron (IFN), and the role of signal transducer and activator JAK phosphorylates signal transducer and activator of tran‑ of transcription 1 (STAT1). HepG2.2.15 cells were stimulated scription (STAT) in the cytoplasm, which then forms STAT1/2 with a long‑term (6‑24 weeks) low‑dose interferon (IFN)α‑2b heterodimers and is transported to the nucleus to interact with (10‑70 IU/ml), so as to construct and screen a HepG2.2.15 IFN‑stimulated response elements (ISRE). This initiates the cell model resistant to IFNα‑2b. The changes of STAT1 and transcription of IFN‑stimulated genes (ISGs), resulting in other proteins in the JAK‑STAT signaling pathway, before and proteins which exert direct or indirect antiviral effects (8), after drug resistance, were compared. The phosphorylation of such as double‑stranded RNA‑dependent protease (Protein STAT1 in HepG2.2.15 cells resistant to IFNα‑2b was signifi‑ Kinase r; RKR) and 2',5'‑oligoadenylate synthetase 1 (OAS1), cantly decreased, and the expression level of 2',5'‑oligoadenylate anti‑myxovirus protein (myxovirus resistance protein A; synthetase 1 was downregulated.
    [Show full text]
  • PRMT5-CATALYZED ARGININE METHYLATION of NF-Κb P65 IN
    PRMT5-CATALYZED ARGININE METHYLATION OF NF-κB p65 IN THE ENDOTHELIAL CELL INDUCTION OF PRO-INFLAMMATORY CHEMOKINES by DANIEL PELLERIN HARRIS Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Advisor: Paul E. DiCorleto, Ph.D. Department of Physiology and Biophysics CASE WESTERN RESERVE UNIVERSITY January, 2016 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Daniel P. Harris candidate for the Doctor of Philosophy degree *. Thomas N. Nosek, Ph.D., Committee Chair Paul E. DiCorleto, Ph.D. Cathleen R. Carlin, Ph.D. George R. Dubyak, Ph.D. Paul L. Fox, Ph.D. Mukesh K. Jain, M.D. July 27th, 2015 *We also certify that written approval has been obtained for any proprietary material contained therein. iii DEDICATION This dissertation is dedicated to my great-grandparents, Mark and Madeline Pellerin, and my parents Steve and Madeline Harris, for showing me how to live with grace and kindness. i TABLE OF CONTENTS List of Tables ....................................................................................................... 4 List of Figures ...................................................................................................... 5 Acknowledgements ............................................................................................ 6 List of Abbreviations ......................................................................................... 11 Abstract .............................................................................................................
    [Show full text]
  • 1541-7786.MCR-09-0417.Full.Pdf
    Published Online First on April 6, 2010 Cell Cycle, Cell Death, and Senescence Molecular Cancer Research The Intracellular Delivery of a Recombinant Peptide Derived from the Acidic Domain of PIAS3 Inhibits STAT3 Transactivation and Induces Tumor Cell Death Corina Borghouts, Hanna Tittmann, Natalia Delis, Marisa Kirchenbauer, Boris Brill, and Bernd Groner Abstract Signaling components, which confer an “addiction” phenotype on cancer cells, represent promising drug tar- gets. The transcription factor signal transducers and activators of transcription 3 (STAT3) is constitutively ac- tivated in many different types of tumor cells and its activity is indispensible in a large fraction. We found that the expression of the endogenous inhibitor of STAT3, protein inhibitor of activated STAT3 (PIAS3), positively correlates with STAT3 activation in normal cells. This suggests that PIAS3 controls the extent and the duration of STAT3 activity in normal cells and thus prevents its oncogenic function. In cancer cells, however, the ex- pression of PIAS3 is posttranscriptionally suppressed, possibly enhancing the oncogenic effects of activated STAT3. We delimited the interacting domains of STAT3 and PIAS3 and identified a short fragment of the COOH-terminal acidic region of PIAS3, which binds strongly to the coiled-coil domain of STAT3. This PIAS3 fragment was used to derive the recombinant STAT3-specific inhibitor rPP-C8. The addition of a protein trans- duction domain allowed the efficient internalization of rPP-C8 into cancer cells. This resulted in the suppression of STAT3 target gene expression, in the inhibition of migration and proliferation, and in the induction of μ apoptosis at low concentrations [half maximal effective concentration (EC50), <3 mol/L].
    [Show full text]
  • Signal Transducer and Activator of Transcription 5A/B in Prostate and Breast Cancers
    Endocrine-Related Cancer (2008) 15 367–390 REVIEW Signal transducer and activator of transcription 5A/B in prostate and breast cancers Shyh-Han Tan and Marja T Nevalainen Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, BLSB 309, Philadelphia, Pennsylvania 19107, USA (Correspondence should be addressed to M T Nevalainen; Email: [email protected]) Abstract Protein kinase signaling pathways, such as Janus kinase 2-Signal transducer and activator of transcription 5A/B (JAK2-STAT5A/B), are of significant interest in the search for new therapeutic strategies in both breast and prostate cancers. In prostate cancer, the components of the JAK2- STAT5A/B signaling pathway provide molecular targets for small-molecule inhibition of survival and growth signals of the cells. At the same time, new evidence suggests that the STAT5A/B signaling pathway is involved in the transition of organ-confined prostate cancer to hormone- refractory disease. This implies that the active JAK2-STAT5A/B signaling pathway potentially provides the means for pharmacological intervention of clinical prostate cancer progression. In addition, active STAT5A/B may serve as a prognostic marker for identification of those primary prostate cancers that are likely to progress to aggressive disease. In breast cancer, the role of STAT5A/B is more complex. STAT5A/B may have a dual role in the regulation of malignant mammary epithelium. Data accumulated from mouse models of breast cancer suggest that in early stages of breast cancer STAT5A/B may promote malignant transformation and enhance growth of the tumor. This is in contrast to established breast cancer, where STAT5A/B may mediate the critical cues for maintaining the differentiation of mammary epithelium.
    [Show full text]
  • From 1957 to Nowadays: a Brief History of Epigenetics
    International Journal of Molecular Sciences Review From 1957 to Nowadays: A Brief History of Epigenetics Paul Peixoto 1,2, Pierre-François Cartron 3,4,5,6,7,8, Aurélien A. Serandour 3,4,6,7,8 and Eric Hervouet 1,2,9,* 1 Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; [email protected] 2 EPIGENEXP Platform, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France 3 CRCINA, INSERM, Université de Nantes, 44000 Nantes, France; [email protected] (P.-F.C.); [email protected] (A.A.S.) 4 Equipe Apoptose et Progression Tumorale, LaBCT, Institut de Cancérologie de l’Ouest, 44805 Saint Herblain, France 5 Cancéropole Grand-Ouest, Réseau Niches et Epigénétique des Tumeurs (NET), 44000 Nantes, France 6 EpiSAVMEN Network (Région Pays de la Loire), 44000 Nantes, France 7 LabEX IGO, Université de Nantes, 44000 Nantes, France 8 Ecole Centrale Nantes, 44300 Nantes, France 9 DImaCell Platform, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France * Correspondence: [email protected] Received: 9 September 2020; Accepted: 13 October 2020; Published: 14 October 2020 Abstract: Due to the spectacular number of studies focusing on epigenetics in the last few decades, and particularly for the last few years, the availability of a chronology of epigenetics appears essential. Indeed, our review places epigenetic events and the identification of the main epigenetic writers, readers and erasers on a historic scale. This review helps to understand the increasing knowledge in molecular and cellular biology, the development of new biochemical techniques and advances in epigenetics and, more importantly, the roles played by epigenetics in many physiological and pathological situations.
    [Show full text]
  • Expression of Androgen Receptor Coregulators in Prostate Cancer
    1032 Vol. 10, 1032–1040, February 1, 2004 Clinical Cancer Research Expression of Androgen Receptor Coregulators in Prostate Cancer Marika J. Linja,1 Kati P. Porkka,1 Conclusions: These findings suggest that the decreased Zhikang Kang,3 Kimmo J. Savinainen,1 expression of PIAS1 and SRC1 could be involved in the progression of prostate cancer. In addition, gene amplifica- Olli A. Ja¨nne,3 Teuvo L. J. Tammela,2 4 3 tion of SRC1 in one of the xenografts implies that, in some Robert L. Vessella, Jorma J. Palvimo, and tumors, genetic alteration of SRC1 may provide a growth 1 Tapio Visakorpi advantage. 1Laboratory of Cancer Genetics, Institute of Medical Technology and 2Department of Urology, University of Tampere and Tampere University Hospital, Tampere, Finland; 3Institute of Biomedicine, INTRODUCTION 4 University of Helsinki, Helsinki, Finland; and Department of The critical role of androgens in the development of pros- Urology, University of Washington, Seattle, Washington tate cancer is indicated, for example, by the fact that prostate cancer does not develop in men castrated early in their life (1). ABSTRACT In addition, more that 50 years ago, Huggins and Hodges (2) Purpose: The androgen receptor (AR)-mediated signal- showed that hormonal therapy is an effective treatment for ing pathway seems to be essentially involved in the develop- prostate cancer. Subsequently, androgen withdrawal has become ment and progression of prostate cancer. In vitro studies the standard and is practically the only effective treatment for have shown that altered expression of AR coregulators may advanced prostate cancer. Although most prostate carcinomas significantly modify transcriptional activity of AR, suggest- are originally androgen dependent, they eventually become hor- ing that these coregulators could also contribute to the mone refractory during treatment (3).
    [Show full text]
  • Materials Express
    Materials Express 2158-5849/2020/10/1836/010 Copyright © 2020 by American Scientific Publishers All rights reserved. doi:10.1166/mex.2020.1822 Printed in the United States of America www.aspbs.com/mex Upregulation of signal transducer and activator of transcription 4 promotes osteoblast activity by activating AMP-activated protein kinase based on cationic liposome transfection Tao Jiang1,4,†, Qingzhen Chen1,2,†,MinShao2,∗, Zhen Shen3, Gang Wang3, Qinsheng Wang2, and Zhenming Zeng2 1The Third Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, PR China 2Department of Orthopedics, The Third Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510240, Guangdong, PR China 3The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, PR China 4 Department of Orthopedics, GuangdongIP: 192.168.39.151 Second Traditional On: Thu, Chinese 30 Sep Medicine 2021 19:20:15 Hospital, Guangzhou 510095, Guangdong, PR China Copyright: American Scientific Publishers Delivered by Ingenta Article ABSTRACT Activation of Protein Kinase AMP-Activated Catalytic Subunit Alpha (AMPK) is an important regulatory path- way for osteogenic differentiation. STAT4 acts as a transcriptional activity factor to regulate the transcription of many genes and is potentially a regulatory factor for AMPK transcription activity. To confirm the regulatory effect of STAT4 on AMPK and the effect of STAT4 on osteogenic differentiation, the promoter sequence of AMPK was analyzed via bioinformatics, the STAT4 overexpression vector was constructed and transfected into human osteoblast-like cells MG-63 by cationic liposome, fluorescence quantitative PCR (RT-qPCR) and western blotting technologies were used to detect the effect of STAT4 on the expression of AMPK.MTT and ALP activity assays were also used to verify the effect of STAT4 on the proliferation and maturation of osteoblasts by regulating AMPK expression.
    [Show full text]
  • Modulation of STAT Signaling by STAT-Interacting Proteins
    Oncogene (2000) 19, 2638 ± 2644 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Modulation of STAT signaling by STAT-interacting proteins K Shuai*,1 1Departments of Medicine and Biological Chemistry, University of California, Los Angeles, California, CA 90095, USA STATs (signal transducer and activator of transcription) play important roles in numerous cellular processes Interaction with non-STAT transcription factors including immune responses, cell growth and dierentia- tion, cell survival and apoptosis, and oncogenesis. In Studies on the promoters of a number of IFN-a- contrast to many other cellular signaling cascades, the induced genes identi®ed a conserved DNA sequence STAT pathway is direct: STATs bind to receptors at the named ISRE (interferon-a stimulated response element) cell surface and translocate into the nucleus where they that mediates IFN-a response (Darnell, 1997; Darnell function as transcription factors to trigger gene activa- et al., 1994). Stat1 and Stat2, the ®rst known members tion. However, STATs do not act alone. A number of of the STAT family, were identi®ed in the transcription proteins are found to be associated with STATs. These complex ISGF-3 (interferon-stimulated gene factor 3) STAT-interacting proteins function to modulate STAT that binds to ISRE (Fu et al., 1990, 1992; Schindler et signaling at various steps and mediate the crosstalk of al., 1992). ISGF-3 consists of a Stat1:Stat2 heterodimer STATs with other cellular signaling pathways. This and a non-STAT protein named p48, a member of the article reviews the roles of STAT-interacting proteins in IRF (interferon regulated factor) family (Levy, 1997).
    [Show full text]
  • Expression of SOCS1 and SOCS3 Genes Is Differentially Regulated in Breast Cancer Cells in Response to Proinflammatory Cytokine and Growth Factor Signals
    Oncogene (2007) 26, 1941–1948 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc ORIGINAL ARTICLE Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals MK Evans1, C-R Yu2, A Lohani1, RM Mahdi2, X Liu2, AR Trzeciak1 and CE Egwuagu2 1Laboratory of Cellular and Molecular Biology, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA and 2Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA DNA-hypermethylation of SOCS genes in breast, ova- Keywords: breast-cancer cells; SOCS; breast cancer; STAT; rian, squamous cell and hepatocellular carcinoma has led BRCA1; DNA hypermethylation; interferon to speculation that silencing of SOCS1 and SOCS3 genes might promote oncogenic transformation of epithelial tissues. To examine whether transcriptional silencing of SOCS genes is a common feature of human carcinoma, we have investigated regulation of SOCS genes expression by Introduction IFNc, IGF-1 and ionizing radiation, in a normal human mammary epithelial cell line (AG11134), two breast- Development of the mammary gland is regulated by cancer cell lines (MCF-7, HCC1937) and three prostate factors that coordinate proliferation, differentiation, cancer cell lines. Compared to normal breast cells, we maturation and apoptosis of mammary epithelial cells. observe a high level constitutive expression of SOCS2, Exquisite control of the initiation, strength and duration SOCS3, SOCS5, SOCS6, SOCS7, CIS and/or SOCS1 of signals from the diverse array of cytokines and genes in the human cancer cells. In MCF-7 and HCC1937 growth factors in mammalian breast is essential to the breast-cancer cells, transcription of SOCS1 is dramati- timely initiation of the menstrual cycle, lactation or cally up-regulated by IFNc and/or ionizing-radiation breast lobule involution (Medina, 2005).
    [Show full text]